Livongo Studies Leverage Proprietary Data and Remote Monitoring to Reveal Unique Diabetes Management Insights
18 Junho 2020 - 2:30PM
Livongo Health, Inc. (Nasdaq: LVGO), the leading Applied
Health Signals company empowering people with chronic conditions to
live better and healthier lives, today announced the findings of
two studies that demonstrate how remote monitoring technologies can
utilize continuous and unique data insights via its AI+AI® engine
to better inform care decisions and outcomes. The research findings
were presented at the American Diabetes Association’s 80th
Scientific Sessions: A Virtual Experience held on June 12-16,
2020.
The first study, Predictors of Emergency
Department and Inpatient Admissions after Hypo- and Hyperglycemic
Events: Leveraging Remote Monitoring Data of People with
Diabetes, included 7,633 study participants and used
Livongo’s cellular-enabled blood glucose monitor and remote
monitoring capabilities to determine specific predictors which may
lead to a hypoglycemic or hyperglycemic event. The study determined
that a gap in days between checking, more ‘Missed Medication’ tags,
fewer ‘Before Breakfast’ tags, new users of oral diabetes
medications, and other factors were predictors associated with
future emergency department and inpatient visits due to a
hypoglycemic event. It also found that models pairing blood glucose
values with rich data including time of day, meal tags, medication
use, and feeling tags are more likely to predict those who are at a
higher-risk of costly care interventions than models using blood
glucose data alone.
The second study, Is Activation,
Behaviors, and Attitudes to Managing Care Associated with
Utilization of a Remote Diabetes Monitoring Platform (RDMP) and
Improvement of A1c, was conducted in collaboration with
Eli Lilly & Company and included 1,089 participants. The study
found a direct correlation between improvements in Diabetes
Empowerment Scale-Short Form (DES-SF) and increased platform
utilization. In addition, participants who used the Livongo
platform more regularly and those who achieved measurable
improvements in Diabetes Distress Scale 17 (DDS17) experienced
better glycemic control.
“Through Livongo’s ability to collect a breadth
of real-time data points, including meal tags and feeling tags, we
are able to build out comprehensive Member profiles and direct
interventions and features from our platform that lead to improved
clinical outcomes,” said Dr. Bimal Shah, Chief Medical Officer of
Livongo and senior author of the studies. “As Livongo’s AI+AI
engine aggregates more data, our platform continues to improve by
providing a more personalized care experience. We are able to
leverage a combination of machine learning and clinical studies to
continue to improve outcomes, drive down health care costs, improve
utilization, and empower people to better manage their
diabetes.”
Through its AI+AI engine, Livongo uses a
connected ecosystem to aggregate data, which includes
cellular-enabled devices and integration with continuous glucose
monitors, and then applies advanced data science to create detailed
Member profiles that includes personal health and medication
trends. Livongo provides Members with cellular-enabled devices,
supplies, and access to digital coaching and time with certified
health coaches for real-time support and goal setting at no
cost.
Last year at the American Diabetes Association’s
79th Scientific Sessions held in San Francisco, California, Livongo
announced a separate study in collaboration with Eli Lilly &
Company that demonstrated 94 percent of Livongo program Members who
participated in a program survey achieved improved Diabetes
Empowerment Scale – Short Form (DES-SF) or Diabetes Distress Scale
2 (DDS2) in year one; effectively improving confidence in diabetes
self-management while decreasing burnout related to diabetes
management.
About Livongo
Livongo empowers people with chronic conditions
to live better and healthier lives, beginning with diabetes and now
including hypertension, weight management, diabetes prevention, and
behavioral health. Livongo pioneered the category of Applied Health
Signals to offer Members clinically-based insights that focus on
the whole person and make it easier to stay healthy. Using its
AI+AI® engine, Livongo's team of data scientists aggregate and
interpret substantial amounts of health data and information to
create actionable, personalized, and timely health signals
delivered to Livongo Members exactly when and where they need them.
The Livongo approach delivers better clinical and financial
outcomes while creating a different and better experience for
people with chronic conditions. For more information,
visit: www.livongo.com or engage with Livongo
on LinkedIn or Twitter.
Media Contacts:
John Hallockpress@livongo.com617-615-7712
Or
Jake Mazankepress@livongo.com630-640-5253
Investor Contact:
Jason PlagmanInvestor-relations@livongo.com785-550-6048
Livongo Health (NASDAQ:LVGO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Livongo Health (NASDAQ:LVGO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024